Hospital
Champlain Valley Physicians Hospital Medical Center
Champlain Valley Physicians Hospital Medical Center was paid $35.88M by Medicaid between Jan 2018 and Dec 2024, across 372 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 9.2% of everything it billed.
33Billing provider infoCHAMPLAIN VALLEY PHYSICIANS HOSPITAL MEDICAL CENTER
PLATTSBURGH, NY 12901
PLATTSBURGH, NY 12901
33aNPI1033270699assigned 12/13/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$35.88M
24GClaims791,887
24DCodes billed372
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#40 of 231
Median peer was paid$561K
This provider vs. median64×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,990 | $135K | |
| 2019 | 46,778 | $1.56M | |
| 2020 | 122,983 | $4.29M | |
| 2021 | 154,834 | $5.76M | |
| 2022 | 162,500 | $10.15M | |
| 2023 | 172,072 | $8.32M | |
| 2024incomplete | 128,730 | $5.67M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.2% | 22,043 | 20,093 | $3.30M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.4% | 20,465 | 19,064 | $3.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.5% | 15,590 | 14,840 | $2.68M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.1% | 15,557 | 14,469 | $2.19M |
| 36415 | Collection of venous blood by venipuncture | 5.6% | 45,768 | 37,007 | $2.03M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.2% | 20,214 | 18,745 | $1.51M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 9,966 | 9,282 | $1.27M |
| 80053 | Comprehensive metabolic panel | 3.1% | 47,104 | 41,064 | $1.11M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.0% | 4,783 | 3,408 | $1.07M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.6% | 13,368 | 5,343 | $937K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 3,581 | 3,466 | $868K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.3% | 5,578 | 5,368 | $830K |
360 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 4,148 | $742K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.0% | 3,737 | $704K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 2,204 | $631K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.7% | 16,407 | $623K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.4% | 5,131 | $517K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 1,479 | $393K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 14,458 | $328K |
| 81025 | <1% | 8,260 | $327K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,229 | $326K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,302 | $321K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 822 | $299K |
| 59025 | Fetal non-stress test | <1% | 1,521 | $287K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,757 | $283K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 923 | $267K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,487 | $259K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,895 | $245K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 459 | $245K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,989 | $226K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,083 | $215K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,022 | $214K |
| 20610 | <1% | 682 | $203K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 663 | $196K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,899 | $192K |
| 93976 | <1% | 482 | $184K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,664 | $183K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,185 | $176K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 529 | $176K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,443 | $172K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 922 | $153K |
| 76937 | <1% | 910 | $152K | |
| 97161 | <1% | 1,631 | $152K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,048 | $140K |
| 76000 | <1% | 527 | $140K | |
| 36416 | <1% | 2,764 | $135K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 915 | $131K |
| 80061 | Lipid panel | <1% | 14,719 | $130K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 170 | $123K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,850 | $122K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,015 | $122K |
| 86850 | <1% | 2,136 | $120K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,894 | $119K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 17,225 | $118K |
| 94060 | <1% | 827 | $115K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,667 | $109K |
| 71250 | <1% | 683 | $104K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,678 | $103K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 3,123 | $101K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 532 | $101K |
| 93356 | <1% | 904 | $99K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,230 | $95K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 46,302 | $89K |
| 87631 | <1% | 1,203 | $84K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 344 | $83K |
| 97162 | <1% | 783 | $77K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,055 | $77K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 455 | $76K |
| 93017 | <1% | 902 | $75K | |
| 71271 | <1% | 616 | $74K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 910 | $74K |
| 88342 | <1% | 789 | $69K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,605 | $66K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,317 | $62K |
| 96415 | <1% | 129 | $62K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,733 | $61K |
| G0378 | Hospital observation service, per hour | <1% | 1,211 | $58K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 167 | $54K |
| 12001 | <1% | 121 | $54K | |
| 93225 | <1% | 660 | $54K | |
| 76770 | <1% | 153 | $53K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 108 | $52K |
| 87653 | <1% | 634 | $51K | |
| 72141 | <1% | 178 | $51K | |
| 93296 | <1% | 565 | $50K | |
| 76775 | <1% | 688 | $49K | |
| 86901 | <1% | 2,082 | $48K | |
| 93971 | <1% | 721 | $44K | |
| 84439 | <1% | 6,121 | $43K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,018 | $43K |
| 90715 | <1% | 1,729 | $42K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 289 | $39K |
| 90686 | <1% | 1,540 | $39K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 775 | $38K |
| 86900 | <1% | 2,084 | $37K | |
| 82728 | <1% | 4,303 | $37K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,893 | $36K |
| 82607 | <1% | 3,713 | $36K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,275 | $35K |
| 94726 | <1% | 621 | $33K | |
| 87070 | <1% | 4,785 | $33K | |
| 83880 | <1% | 1,122 | $33K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,161 | $31K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 25 | $30K |
| 82803 | <1% | 1,646 | $29K | |
| 76642 | <1% | 1,041 | $26K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 371 | $26K |
| 82746 | <1% | 2,663 | $26K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,588 | $24K |
| 83970 | <1% | 613 | $23K | |
| 84153 | <1% | 1,470 | $22K | |
| 86618 | <1% | 1,663 | $21K | |
| 93270 | <1% | 50 | $21K | |
| 97165 | <1% | 269 | $21K | |
| 93308 | <1% | 93 | $21K | |
| 85610 | <1% | 5,714 | $21K | |
| 84702 | <1% | 3,435 | $21K | |
| 93458 | <1% | 25 | $21K | |
| 80076 | <1% | 832 | $20K | |
| 73221 | <1% | 64 | $19K | |
| 86803 | <1% | 3,157 | $19K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,003 | $19K |
| 70498 | <1% | 64 | $18K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 140 | $17K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 539 | $16K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 38 | $16K |
| 81001 | <1% | 14,019 | $15K | |
| 87077 | <1% | 2,980 | $15K | |
| 87660 | <1% | 2,030 | $15K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 462 | $14K |
| 87186 | <1% | 3,564 | $14K | |
| 76536 | <1% | 552 | $14K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 42 | $14K |
| 87480 | <1% | 1,914 | $13K | |
| 83735 | <1% | 10,338 | $13K | |
| 83540 | <1% | 3,737 | $13K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 413 | $13K |
| 0352U | <1% | 246 | $13K | |
| 87510 | <1% | 1,890 | $13K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $13K |
| 84403 | <1% | 660 | $12K | |
| 84466 | <1% | 1,382 | $12K | |
| 77066 | Tomosynthesis, mammo | <1% | 195 | $12K |
| 88304 | <1% | 463 | $12K | |
| 77065 | Tomosynthesis, mammo | <1% | 171 | $11K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 248 | $11K |
| 85027 | <1% | 5,246 | $11K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 80 | $11K |
| 99385 | <1% | 68 | $11K | |
| 83655 | <1% | 773 | $10K | |
| 80081 | <1% | 283 | $10K | |
| 82570 | <1% | 3,039 | $10K | |
| 84146 | <1% | 727 | $10K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 161 | $10K |
| 82043 | <1% | 2,646 | $10K | |
| 43235 | <1% | 14 | $9K | |
| 72100 | <1% | 1,330 | $9K | |
| 87081 | <1% | 2,134 | $9K | |
| 82670 | <1% | 408 | $9K | |
| 87150 | <1% | 150 | $8K | |
| 82784 | <1% | 1,036 | $8K | |
| 90677 | <1% | 163 | $8K | |
| 83001 | <1% | 577 | $8K | |
| 88307 | <1% | 24 | $8K | |
| 84481 | <1% | 1,115 | $8K | |
| 86140 | <1% | 3,075 | $7K | |
| 76818 | <1% | 66 | $7K | |
| 73630 | <1% | 1,767 | $7K | |
| 83550 | <1% | 1,948 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,489 | $7K |
| 86038 | <1% | 1,421 | $6K | |
| 73030 | <1% | 1,488 | $6K | |
| 70491 | <1% | 27 | $6K | |
| 88341 | <1% | 39 | $6K | |
| 73564 | <1% | 1,134 | $6K | |
| 82565 | <1% | 545 | $6K | |
| 70486 | <1% | 60 | $6K | |
| 82248 | <1% | 2,176 | $6K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 891 | $6K |
| 96367 | <1% | 103 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,191 | $5K |
| 51798 | <1% | 19 | $5K | |
| 83690 | <1% | 7,621 | $5K | |
| 86141 | <1% | 624 | $5K | |
| 84100 | <1% | 1,730 | $5K | |
| 85651 | <1% | 3,169 | $5K | |
| 73610 | <1% | 1,778 | $4K | |
| 76882 | <1% | 43 | $4K | |
| 77062 | <1% | 78 | $4K | |
| 99406 | <1% | 122 | $4K | |
| 86480 | <1% | 74 | $4K | |
| 83002 | <1% | 288 | $4K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 102 | $4K |
| 73130 | <1% | 1,251 | $4K | |
| 87340 | <1% | 844 | $4K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 26 | $4K |
| 73560 | <1% | 977 | $4K | |
| 72114 | <1% | 238 | $4K | |
| 86431 | <1% | 851 | $4K | |
| 10060 | <1% | 12 | $4K | |
| 87468 | <1% | 119 | $4K | |
| 82950 | <1% | 1,313 | $3K | |
| 85730 | <1% | 1,740 | $3K | |
| 84480 | <1% | 732 | $3K | |
| 84703 | <1% | 1,023 | $3K | |
| 86665 | <1% | 94 | $3K | |
| 86592 | <1% | 1,594 | $3K | |
| 84550 | <1% | 991 | $3K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 21 | $3K |
| 73502 | <1% | 641 | $3K | |
| 0124A | <1% | 72 | $3K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 45 | $3K |
| 84156 | <1% | 1,212 | $3K | |
| 29125 | <1% | 13 | $3K | |
| 94729 | <1% | 578 | $3K | |
| 84484 | <1% | 6,778 | $2K | |
| 87484 | <1% | 117 | $2K | |
| 73110 | <1% | 1,047 | $2K | |
| 85379 | <1% | 1,942 | $2K | |
| 93226 | <1% | 39 | $2K | |
| 90656 | <1% | 136 | $2K | |
| 86706 | <1% | 453 | $2K | |
| 93242 | <1% | 29 | $2K | |
| 87205 | <1% | 1,223 | $2K | |
| 72050 | <1% | 208 | $2K | |
| 90732 | <1% | 16 | $2K | |
| 0011A | <1% | 144 | $2K | |
| 81003 | <1% | 5,061 | $2K | |
| 87469 | <1% | 96 | $2K | |
| 82105 | <1% | 511 | $2K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 12 | $2K |
| 99386 | <1% | 12 | $2K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $2K |
| 99241 | <1% | 12 | $2K | |
| 72070 | <1% | 234 | $2K | |
| 74018 | <1% | 410 | $2K | |
| 92557 | <1% | 37 | $2K | |
| 36592 | <1% | 188 | $2K | |
| 86364 | <1% | 251 | $1K | |
| 81015 | <1% | 999 | $1K | |
| 86664 | <1% | 94 | $1K | |
| 77080 | <1% | 65 | $1K | |
| 77061 | <1% | 12 | $1K | |
| 86376 | <1% | 105 | $1K | |
| 87040 | <1% | 1,240 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,092 | $1K |
| 92567 | <1% | 41 | $1K | |
| 82150 | <1% | 308 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,383 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,890 | $969.05 |
| 73140 | <1% | 308 | $954.71 | |
| 86787 | <1% | 582 | $948.17 | |
| 86235 | <1% | 98 | $917.88 | |
| 82550 | <1% | 620 | $893.71 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 463 | $881.16 |
| 88185 | <1% | 13 | $873.32 | |
| 72110 | <1% | 52 | $860.55 | |
| 87625 | <1% | 65 | $763.85 | |
| 70496 | <1% | 26 | $745.17 | |
| 83605 | <1% | 2,332 | $733.58 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,626 | $731.42 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 27 | $659.32 |
| 83615 | <1% | 373 | $648.70 | |
| 76870 | <1% | 29 | $602.30 | |
| 86039 | <1% | 122 | $563.83 | |
| 86704 | <1% | 120 | $549.96 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,069 | $548.31 |
| 86334 | <1% | 41 | $536.96 | |
| 87641 | <1% | 13 | $531.95 | |
| 73080 | <1% | 229 | $494.72 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,777 | $456.82 |
| 86762 | <1% | 58 | $453.27 | |
| 88142 | <1% | 19 | $451.38 | |
| 85652 | <1% | 229 | $352.68 | |
| 90678 | <1% | 14 | $347.64 | |
| 84145 | <1% | 898 | $342.21 | |
| 92511 | <1% | 39 | $332.45 | |
| 84165 | <1% | 74 | $330.11 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 14 | $300.00 |
| 93297 | <1% | 126 | $299.44 | |
| 86800 | <1% | 27 | $296.20 | |
| 84144 | <1% | 13 | $264.92 | |
| 84520 | <1% | 72 | $217.85 | |
| 73090 | <1% | 116 | $215.86 | |
| 73590 | <1% | 121 | $215.30 | |
| 82962 | <1% | 3,448 | $210.28 | |
| 86160 | <1% | 13 | $199.50 | |
| 82977 | <1% | 43 | $194.60 | |
| 81329 | <1% | 40 | $191.80 | |
| 82533 | <1% | 14 | $190.71 | |
| 0012A | <1% | 14 | $185.22 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,310 | $180.91 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,191 | $141.18 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,364 | $140.20 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 872 | $139.27 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,323 | $130.71 |
| 86780 | <1% | 25 | $127.60 | |
| 87899 | <1% | 12 | $118.86 | |
| 80306 | <1% | 753 | $115.81 | |
| 80365 | <1% | 29 | $114.93 | |
| 99152 | <1% | 1,226 | $109.63 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 267 | $106.16 |
| 86308 | <1% | 65 | $101.99 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,524 | $98.47 |
| 85045 | <1% | 42 | $95.14 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,015 | $94.85 |
| 83993 | <1% | 13 | $94.83 | |
| 88184 | <1% | 13 | $89.70 | |
| 82378 | <1% | 15 | $86.70 | |
| 80164 | <1% | 13 | $84.88 | |
| 87210 | <1% | 14 | $83.06 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,394 | $81.65 |
| 83037 | <1% | 137 | $66.65 | |
| 73522 | <1% | 12 | $62.51 | |
| 80178 | <1% | 13 | $62.14 | |
| 93298 | <1% | 115 | $60.50 | |
| 86225 | <1% | 12 | $51.57 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,748 | $51.18 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 923 | $51.16 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,152 | $48.78 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,861 | $48.34 |
| 87184 | <1% | 12 | $46.13 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,022 | $41.71 |
| 80179 | <1% | 496 | $40.67 | |
| 72170 | <1% | 12 | $30.00 | |
| 85046 | <1% | 28 | $29.39 | |
| 84460 | <1% | 13 | $25.84 | |
| 80143 | <1% | 544 | $24.23 | |
| 82077 | <1% | 774 | $24.18 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 659 | $22.50 |
| 93299 | <1% | 12 | $20.49 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 153 | $19.80 |
| 80329 | <1% | 616 | $16.37 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 346 | $13.52 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 332 | $10.80 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 578 | $10.77 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 272 | $9.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 538 | $8.84 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,250 | $8.23 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 130 | $7.20 |
| 96376 | <1% | 426 | $7.12 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 123 | $7.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 92 | $5.06 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 84 | $4.60 |
| 99153 | Mod sedat endo service >5yrs | <1% | 323 | $3.52 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 364 | $1.82 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 49 | $1.82 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 192 | $1.40 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 360 | $1.08 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 99 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 82 | $0.00 |
| 91322 | 0% | 35 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 68 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 28 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 49 | $0.00 |
| 80305 | 0% | 13 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 68 | $0.00 |
| 81002 | 0% | 177 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 37 | $0.00 |
| 88173 | 0% | 12 | $0.00 | |
| 91312 | 0% | 33 | $0.00 | |
| 81222 | 0% | 32 | $0.00 | |
| C1769 | Guide wire | 0% | 280 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 58 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 176 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 196 | $0.00 |
| 96127 | 0% | 12 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 78 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 56 | $0.00 |
| 90480 | 0% | 37 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 55 | $0.00 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEBEAU, MICHELLE (PRESIDENT/COO)
| Provider | Location | Paid |
|---|---|---|
| Champlain Valley Physicians Hospital Medical Center | Plattsburgh, NY | $3.36M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.